首页 > 最新文献

Trends in cancer最新文献

英文 中文
Reconceptualizing mental health in cancer survivorship. 重新认识癌症幸存者的心理健康。
IF 14.3 1区 医学 Q1 ONCOLOGY
Trends in cancer
Pub Date : 2024-08-01 Epub Date: 2024-06-17 DOI: 10.1016/j.trecan.2024.05.008
Darren Haywood, Roman Kotov, Robert F Krueger, Aidan G C Wright, Miriam K Forbes, Evan Dauer, Frank D Baughman, Susan L Rossell, Nicolas H Hart

Mental health for cancer survivors in both research and clinical applications has strongly adopted a traditional nosological approach, involving the classification of psychopathology into discrete disorders. However, this approach has recently faced considerable criticism due to issues such as high comorbidity and within-disorder symptom heterogeneity across populations. Moreover, there are additional specific issues impacting the validity of traditional approaches in cancer survivorship populations, including the physiological effects of cancer and its treatments. In response, we provide the case for the hierarchical dimensional approach within psycho-oncology, in particular the Hierarchical Taxonomy of Psychopathology (HiTOP). We discuss not only the potential utility of HiTOP to research and clinical applications within psycho-oncology, but also its limitations, and what is required to apply this approach within cancer survivorship.

在研究和临床应用中，癌症幸存者的心理健康问题主要采用传统的分类学方法，将精神病理学分为不同的障碍。然而，这种方法近来受到了相当多的批评，原因是不同人群之间存在高合并率和障碍内症状异质性等问题。此外，传统方法在癌症幸存者群体中的有效性还受到其他特殊问题的影响，包括癌症及其治疗的生理影响。对此，我们提出了肿瘤心理学中的分层维度方法，尤其是精神病理学分层分类法（HiTOP）。我们不仅讨论了 HiTOP 在肿瘤心理学研究和临床应用中的潜在作用，还讨论了它的局限性，以及在癌症幸存者中应用这种方法所需的条件。
{"title":"Reconceptualizing mental health in cancer survivorship.","authors":"Darren Haywood, Roman Kotov, Robert F Krueger, Aidan G C Wright, Miriam K Forbes, Evan Dauer, Frank D Baughman, Susan L Rossell, Nicolas H Hart","doi":"10.1016/j.trecan.2024.05.008","DOIUrl":"10.1016/j.trecan.2024.05.008","url":null,"abstract":"<p><p>Mental health for cancer survivors in both research and clinical applications has strongly adopted a traditional nosological approach, involving the classification of psychopathology into discrete disorders. However, this approach has recently faced considerable criticism due to issues such as high comorbidity and within-disorder symptom heterogeneity across populations. Moreover, there are additional specific issues impacting the validity of traditional approaches in cancer survivorship populations, including the physiological effects of cancer and its treatments. In response, we provide the case for the hierarchical dimensional approach within psycho-oncology, in particular the Hierarchical Taxonomy of Psychopathology (HiTOP). We discuss not only the potential utility of HiTOP to research and clinical applications within psycho-oncology, but also its limitations, and what is required to apply this approach within cancer survivorship.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"677-686"},"PeriodicalIF":14.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards enhancing the predictive value of the microbiota for cancer immunotherapy 提高微生物群对癌症免疫疗法的预测价值
IF 18.4 1区 医学 Q1 ONCOLOGY
Trends in cancer
Pub Date : 2024-07-31 DOI: 10.1016/j.trecan.2024.07.007

The gut microbiota has emerged as a potential determinant of immune checkpoint inhibitor (ICI) response, yet using it as a biomarker remains challenging. A recent study in Cell by Derosa et al. describes a two-tier model based on gut microbiota composition to discriminate responder from non-responder patients with cancer, offering new ideas that could be leveraged in the clinic.

肠道微生物群已成为免疫检查点抑制剂（ICI）反应的潜在决定因素，但将其用作生物标志物仍具有挑战性。Derosa 等人最近在《细胞》（Cell）杂志上发表的一项研究介绍了一种基于肠道微生物群组成的双层模型，用于区分有反应和无反应的癌症患者，提供了可在临床中利用的新思路。
{"title":"Towards enhancing the predictive value of the microbiota for cancer immunotherapy","authors":"","doi":"10.1016/j.trecan.2024.07.007","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.07.007","url":null,"abstract":"<p>The gut microbiota has emerged as a potential determinant of immune checkpoint inhibitor (ICI) response, yet using it as a biomarker remains challenging. A recent study in <em>Cell</em> by <span><span>Derosa <em>et al.</em></span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> describes a two-tier model based on gut microbiota composition to discriminate responder from non-responder patients with cancer, offering new ideas that could be leveraged in the clinic.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"10 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141862968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncology-respirology: a discipline in dire need 肿瘤反应学：一门亟需发展的学科
IF 18.4 1区 医学 Q1 ONCOLOGY
Trends in cancer
Pub Date : 2024-07-26 DOI: 10.1016/j.trecan.2024.07.001

Despite the success of various cancer therapies on patient survival, these treatments can have negative side effects, particularly severe damage to the respiratory system. Given the rise in respiratory-associated illnesses in response to cancer treatment, we urge the field to consider a new discipline referred to as ‘oncology–respirology’ (or onco-respirology).

尽管各种癌症疗法成功地提高了患者的生存率，但这些疗法可能会产生负面影响，尤其是对呼吸系统造成严重损害。鉴于癌症治疗引起的呼吸系统相关疾病的增加，我们敦促该领域考虑建立一门新学科，即 "肿瘤反应学"（或肿瘤反应学）。
{"title":"Oncology-respirology: a discipline in dire need","authors":"","doi":"10.1016/j.trecan.2024.07.001","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.07.001","url":null,"abstract":"<p>Despite the success of various cancer therapies on patient survival, these treatments can have negative side effects, particularly severe damage to the respiratory system. Given the rise in respiratory-associated illnesses in response to cancer treatment, we urge the field to consider a new discipline referred to as ‘oncology–respirology’ (or onco-respirology).</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"14 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141773819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advisory Board and Contents 咨询委员会和内容
IF 18.4 1区 医学 Q1 ONCOLOGY
Trends in cancer
Pub Date : 2024-07-09 DOI: 10.1016/s2405-8033(24)00124-9
No Abstract
无摘要
{"title":"Advisory Board and Contents","authors":"","doi":"10.1016/s2405-8033(24)00124-9","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00124-9","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"17 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141577790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subscription & copyright page 订阅和版权页面
IF 18.4 1区 医学 Q1 ONCOLOGY
Trends in cancer
Pub Date : 2024-07-09 DOI: 10.1016/s2405-8033(24)00127-4
No Abstract
无摘要
{"title":"Subscription & copyright page","authors":"","doi":"10.1016/s2405-8033(24)00127-4","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00127-4","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"27 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141572587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COX2-dependent suppression of anticancer immunity. COX2 依赖性抑制抗癌免疫。
IF 14.3 1区 医学 Q1 ONCOLOGY
Trends in cancer
Pub Date : 2024-07-01 Epub Date: 2024-05-30 DOI: 10.1016/j.trecan.2024.05.006
María Cecilia Lira, Lorenzo Galluzzi, Claire Vanpouille-Box

Prostaglandin E2 (PGE2) is well known to promote tumor progression by boosting cancer cell proliferation while inhibiting anticancer immunity. Recent data from Lacher et al. and Morotti et al. demonstrate that one of the mechanisms through which PGE2 suppresses tumor-targeting immune responses involves downregulation of interleukin 2 (IL2) receptors and consequent inhibition of mitochondrial metabolism in T cells.

众所周知，前列腺素 E2（PGE2）可促进癌细胞增殖，同时抑制抗癌免疫，从而促进肿瘤进展。Lacher 等人和 Morotti 等人的最新数据表明，PGE2 抑制肿瘤靶向免疫反应的机制之一是下调白细胞介素 2（IL2）受体，从而抑制 T 细胞的线粒体代谢。
{"title":"COX2-dependent suppression of anticancer immunity.","authors":"María Cecilia Lira, Lorenzo Galluzzi, Claire Vanpouille-Box","doi":"10.1016/j.trecan.2024.05.006","DOIUrl":"10.1016/j.trecan.2024.05.006","url":null,"abstract":"<p><p>Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) is well known to promote tumor progression by boosting cancer cell proliferation while inhibiting anticancer immunity. Recent data from Lacher et al. and Morotti et al. demonstrate that one of the mechanisms through which PGE<sub>2</sub> suppresses tumor-targeting immune responses involves downregulation of interleukin 2 (IL2) receptors and consequent inhibition of mitochondrial metabolism in T cells.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"573-575"},"PeriodicalIF":14.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new BRAF inhibitor breaks resistance barriers. 一种新型 BRAF 抑制剂打破了抗药性障碍。
IF 14.3 1区 医学 Q1 ONCOLOGY
Trends in cancer
Pub Date : 2024-07-01 Epub Date: 2024-06-11 DOI: 10.1016/j.trecan.2024.05.009
Morena Scotece, Matthias Drosten

Approved BRAF inhibitors have shown limited clinical benefit due to recurrent disease progression. In a recent Cancer Discovery paper, Yaeger et al. show that a next-generation BRAF inhibitor, PF-07799933, has widespread therapeutic activity in experimental models and patients who were refractory to treatment with approved BRAF inhibitors.

由于疾病复发，已批准的 BRAF 抑制剂临床疗效有限。在最近的一篇《癌症发现》（Cancer Discovery）论文中，Yaeger 等人指出，新一代 BRAF 抑制剂 PF-07799933 在实验模型和对已批准的 BRAF 抑制剂治疗无效的患者中具有广泛的治疗活性。
{"title":"A new BRAF inhibitor breaks resistance barriers.","authors":"Morena Scotece, Matthias Drosten","doi":"10.1016/j.trecan.2024.05.009","DOIUrl":"10.1016/j.trecan.2024.05.009","url":null,"abstract":"<p><p>Approved BRAF inhibitors have shown limited clinical benefit due to recurrent disease progression. In a recent Cancer Discovery paper, Yaeger et al. show that a next-generation BRAF inhibitor, PF-07799933, has widespread therapeutic activity in experimental models and patients who were refractory to treatment with approved BRAF inhibitors.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"576-578"},"PeriodicalIF":14.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancements in combining targeted therapy and immunotherapy for colorectal cancer. 结直肠癌靶向治疗与免疫疗法相结合的进展。
IF 14.3 1区 医学 Q1 ONCOLOGY
Trends in cancer
Pub Date : 2024-07-01 Epub Date: 2024-05-31 DOI: 10.1016/j.trecan.2024.05.001
Manisha Singh, Van Karlyle Morris, Irfan N Bandey, David S Hong, Scott Kopetz

Colorectal cancer (CRC) is a prevalent gastrointestinal cancer posing significant clinical challenges. CRC management traditionally involves surgery, often coupled with chemotherapy. However, unresectable or metastatic CRC (mCRC) presents a complex challenge necessitating innovative treatment strategies. Targeted therapies have emerged as the cornerstone of treatment in such cases, with interventions tailored to specific molecular attributes. Concurrently, immunotherapies have revolutionized cancer treatment by harnessing the immune system to combat malignant cells. This review explores the evolving landscape of CRC treatment, focusing on the synergy between immunotherapies and targeted therapies, thereby offering new avenues for enhancing the effectiveness of therapy for CRC.

结肠直肠癌（CRC）是一种常见的胃肠道癌症，给临床带来了巨大挑战。传统的 CRC 治疗包括外科手术，通常还辅以化疗。然而，无法切除或转移的 CRC（mCRC）是一项复杂的挑战，需要创新的治疗策略。靶向疗法已成为此类病例的治疗基石，可针对特定分子属性进行干预。与此同时，免疫疗法通过利用免疫系统对抗恶性细胞，彻底改变了癌症治疗。本综述探讨了 CRC 治疗不断发展的前景，重点关注免疫疗法和靶向疗法之间的协同作用，从而为提高 CRC 治疗的有效性提供新的途径。
{"title":"Advancements in combining targeted therapy and immunotherapy for colorectal cancer.","authors":"Manisha Singh, Van Karlyle Morris, Irfan N Bandey, David S Hong, Scott Kopetz","doi":"10.1016/j.trecan.2024.05.001","DOIUrl":"10.1016/j.trecan.2024.05.001","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a prevalent gastrointestinal cancer posing significant clinical challenges. CRC management traditionally involves surgery, often coupled with chemotherapy. However, unresectable or metastatic CRC (mCRC) presents a complex challenge necessitating innovative treatment strategies. Targeted therapies have emerged as the cornerstone of treatment in such cases, with interventions tailored to specific molecular attributes. Concurrently, immunotherapies have revolutionized cancer treatment by harnessing the immune system to combat malignant cells. This review explores the evolving landscape of CRC treatment, focusing on the synergy between immunotherapies and targeted therapies, thereby offering new avenues for enhancing the effectiveness of therapy for CRC.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"598-609"},"PeriodicalIF":14.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advisory Board and Contents 咨询委员会和内容
IF 18.4 1区 医学 Q1 ONCOLOGY
Trends in cancer
Pub Date : 2024-06-11 DOI: 10.1016/s2405-8033(24)00100-6
No Abstract
无摘要
{"title":"Advisory Board and Contents","authors":"","doi":"10.1016/s2405-8033(24)00100-6","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00100-6","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"10 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141529783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subscription & copyright page 订阅和版权页面
IF 18.4 1区 医学 Q1 ONCOLOGY
Trends in cancer
Pub Date : 2024-06-11 DOI: 10.1016/s2405-8033(24)00103-1
No Abstract
无摘要
{"title":"Subscription & copyright page","authors":"","doi":"10.1016/s2405-8033(24)00103-1","DOIUrl":"https://doi.org/10.1016/s2405-8033(24)00103-1","url":null,"abstract":"No Abstract","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"40 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141508834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Trends in cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1